Introduction
Duchenne muscular dystrophy (DMD) and the milder phenotype, Becker muscular dystrophy (BMD), are allelic X-linked disorders characterised by progressive degenerative myopathy.
1 DMD and BMD are both due to mutations in the dystrophin gene on Xp21. The severe DMD phenotype is associated with gross rearrangements (about 65% of cases) 2, 3 and smaller mutations (the remaining 35% of cases) [3] [4] [5] which cause premature translational termination and consequently, absence of dystrophin from most ( > 98%) or all muscle cells. 6 The milder variant, BMD, shows a variable phenotype from a slightly less severe, DMD-like condition to very mild symptoms in patients who remain ambulant throughout their lives. In BMD patients, markedly elevated serum creatine kinase activity is observed (more than five fold). The involvement of heart muscle seems more prominent in BMD patients with more mildly affected skeletal muscles. 7 BMD is mostly associated with rearrangements in which the translational reading frame is maintained. 8 In muscle of BMD patients, dystrophin is present at different levels and/or of altered size. 6 The dystrophin gene is the largest gene (2400 kb) 3 known consisting of 79 exons with multiple promoters and alternative splice sites. 9 Purine-rich sequences or exon recognition sequences (ERS) 10 have been reported within some exons of this gene that might act as additional cis elements to permit correct exon recognition. 11 A nonsense mutation in the putative exon 27 ERS has recently been reported to promote skipping of this exon. 12 Similar findings have been described for other human diseases. 13, 14 In none of the cases were nucleotide changes in the splicing consensus sequences found. In this study we show that a nonsense mutation in an ERS-like sequence of exon 29 also induces (partial) skipping leading to grossly variable clinical phenotypes within one BMD family.
Patients, materials and methods

Subjects
The clinical symptoms of the BMD patients in this family are: patient 1, a 58-year-old male, is wheelchair-bound to bridge longer distances and has progressive muscle weakness, kyphoscoliosis and cardiomyopathy. His younger nephew patient 2 aged 23 has only very mild symptoms, whilst the latter's elder brother relative 3 aged 26 had raised serum CK levels only. Both nephews did not show abnormalities of the calves and had normal ECGs. Muscle biopsy specimens of the two nephews were available for dystrophin analysis.
DNA analysis
DNA was extracted from the patients' whole blood, according to the method of Miller et al. 15 Multiplex PCR was performed according to Chamberlain and Beggs 9 and Southern blotting was after Bakker and den Dunnen. 16 Eight highly informative intra-and extragenic STR markers 16 were used for microsatellite genotyping as indicated in Figure 1 . Approximately 200 ng of the PCR product generating the truncated translation product was used for sequence analysis. Sequencing was performed using the Big Dye Terminator Sequencing kit (Applied Biosystems, Nieuwekerk a/d IJssel, Netherlands) on an ABI PRISM 310.
PTT assay RNA was isolated from muscle tissue specimens and whole blood using RNAzol (Campro Scientific, Veerendaal, Netherlands) according to the manufacturer's protocol. RT-PCR and the protein truncation test (PTT) was performed as described by Roest et al.
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Immunohistochemistry Serial unfixed cryostat sections of muscle specimens of family members 2 and 3 were studied for dystrophin and spectrin expression. The following antibodies were used against spectrin (NCL-SPEC1 from Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) and dystrophin (NCL-DYS1/2/3, Novocastra; Mandys108 18 ). The immunohistochemical stainings were done as described previously.
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Results and discussion
Initial mutation analysis of the oldest BMD patient in this family did not show any deletion or duplication in the dystrophin gene. Haplotype analysis of the dystrophin gene region showed the same X chromosome in all three male relatives ( Figure 1 ) suggesting an X-linked inheritance pattern. A muscle biopsy taken from patient 2 showed absence of dystrophin using antibody NCL-DYS1 (Figure 2A ), whereas it was present using NCL-DYS3, MANDYS108 ( Figure 2B ) and NCL-DYS2; spectrin was normally expressed ( Figure 2C ). The same results were found for relative 3. Muscle tissue of patient 1 was not available for protein analysis. By means of Western blot analysis a reduced amount of dystrophin in relatives 2 and 3 was observed. These results confirmed our immuno-histochemical data suggesting a dystrophinopathy in this family. Since the immunohistochemical analysis indicated a mutation in the NCL-DYS1 antigenic region of dystrophin, the corresponding part of the gene (exons encoding amino acids 1181-1388) was analysed using RT-PCR (primerset 2E-2F) and the protein truncation test (PTT). A truncated 32 kDa protein fragment was detected using RNA isolated from the lymphocytes of patient 2 ( Figure 3 ; lane L). Subsequent genomic sequence analysis revealed a nonsense mutation in exon 29 (4148C > T; Arg1314X) of the dystrophin gene. The same nonsense mutation was found in patient 1 and relative 3. Remarkably, using RNA isolated from muscle tissue of patient 2, a near full-size 42 kDa dystrophin peptide was detected in addition to the truncated 32 kDa dystrophin band observed in lymphocytes (Figure 3 ; lane M). Both PTT products were also found in the muscle tissue of relative 3 (not shown). Apparently, splicing regulation in muscle differs from that in blood.
Sequence analysis of the 42 kDa dystrophin encoding fragment showed the absence of exon 29. The original nonsense mutation is apparently bypassed in a percentage of muscle transcripts by altered splicing, ie skipping of exon 29, which restores the dystrophin open reading frame. Since immunohistochemical analysis of these patients showed absence of dystrophin using monoclonal antibody NCL-DYS1, the epitope to which NCL-DYS1 (within amino acids 1181-1388) is directed, has been mapped to exon 29. In this report, we describe a nonsense mutation, expected to cause DMD, in a BMD patient, his mildly affected nephew and his unaffected nephew, the latter with high serum CK levels as the only clinical abnormality. The various clinical features of the three relatives are most likely due to different levels of exon 29 skipping. This apparently leads to a higher level of partly incomplete but functional dystrophin in the mildly affected patient and a proficient level of this protein in his healthy brother.
The consensus sequences splice acceptor and donor sites of exon 29 were unaltered and are weak according to the NetGene2 splice site prediction server. 20 The mutation 4148C > T is predicted to reduce even further the effectiveness of the splice acceptor site of exon 29. We hypothesise that the C to T transversion at the 19th nucleotide of exon 29 may interrupt a potential ERS. Previous reports have described ERSs in dystrophin exons 19 and 27. 21, 12 Alternatively, the not well understood process of nonsense- Figure 2 Immunohistochemical labelling of dystrophin and spectrin in skeletal muscle of patient 2. Serial sections were immunostained with A NCL-DYS1 (within amino acids 1181-1388 of dystrophin); B MANDYS108 (within amino acids 1749-2248 of dystrophin) and C NCL-SPEC1 (spectrin).
Figure 3
Protein truncation test products from primer set 2E-2F (exon 23-32) of normal control muscle and muscle tissue and lymphocytes of patient 2. In control muscle (M) the wild type 52 kDa protein band is shown, in muscle tissue of patient 2 (M), the truncated 32 kDa protein band and the alternatively spliced 42 kDa protein product (exon 29 skipped) is found. In the lymphocytes (L) of patient 2 the truncated 32 kDa protein band is seen only. The size marker was luciferase control (Tnt-kit).
Variable exon skipping within one BMD family IB Ginjaar et al y mediated mRNA decay 22 might be involved, activated by the in-frame stop codon mutation. The same dystrophin nonsense mutation was very recently reported in a family with X-linked early onset dilated cardiomyopathy. 23 Our observations support the development of alternative gene therapy approaches based on modulation of splicing to bypass DMD-causing mutations in the endogenous dystrophin gene. Recent studies show that by using antisense oligonucleotides directed to sites involved in the dystrophin splicing process, the original reading frame can be restored by targeted skipping of specific exons from the pre-mRNA. 21, 24, 25 Consequently, despite an internal in-frame deletion, a partially functional dystrophin may be generated similar to those found in milder BMD patients.
